Lung carcinoma is the leading cause of cancer-related death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majority of cases. Globally, lung cancers are considered to be the leading causes of cancer-related deaths, and non-small cell lung carcinoma (NSCLC) 4 is the predominant type of lung cancer, occurring in 85% of the cases (1, 2). The prognosis of NSCLC is poor, and the survival rate is only 15% after 5 years because many of these patients ultimately do not respond to chemotherapy and radiotherapy due to the presence of CSC (3-5). The CSC have the unique ability to promote tumor growth, recurrence, metastasis, and resistance to treatment (6, 7). Moreover, CD133, a surface glycoprotein with a five-transmembrane domain, has been widely used as a surface marker to identify CSC in many human tumors including NSCLC (8 -12). Although CD133 is expressed in various human tissues, its glycosylated epitopes specific for stem cells may be discordant or sometimes absent, making it difficult to identify this cell population (13). There may be transcriptional or post-translational modifications (14), leading to some degree of alteration in its expression, or variation in its expression in different tumors may be due to the use of antibodies from different clones (12). However, despite these limitations, recent results from different laboratories have shown significant association of CD133 (epitope-1) expression in a population of tumor cells with CSC characteristics in the brain, prostate, liver, and lung (15-18).
Globally, lung cancers are considered to be the leading causes of cancer-related deaths, and non-small cell lung carcinoma (NSCLC) 4 is the predominant type of lung cancer, occurring in 85% of the cases (1, 2) . The prognosis of NSCLC is poor, and the survival rate is only 15% after 5 years because many of these patients ultimately do not respond to chemotherapy and radiotherapy due to the presence of CSC (3) (4) (5) . The CSC have the unique ability to promote tumor growth, recurrence, metastasis, and resistance to treatment (6, 7) . Moreover, CD133, a surface glycoprotein with a five-transmembrane domain, has been widely used as a surface marker to identify CSC in many human tumors including NSCLC (8 -12) . Although CD133 is expressed in various human tissues, its glycosylated epitopes specific for stem cells may be discordant or sometimes absent, making it difficult to identify this cell population (13) . There may be transcriptional or post-translational modifications (14) , leading to some degree of alteration in its expression, or variation in its expression in different tumors may be due to the use of antibodies from different clones (12) . However, despite these limitations, recent results from different laboratories have shown significant association of CD133 (epitope-1) expression in a population of tumor cells with CSC characteristics in the brain, prostate, liver, and lung (15) (16) (17) (18) .
There are now several reports that have further strengthened the concept of CD133ϩve tumor cells as CSC in NSCLC as these tumor cells possess the characteristics of CSC (18 -20) . In contrast to the CD133Ϫve tumor cells, CD133ϩve tumor cells are more tumorigenic and resistant to radiation and anticancer drugs (18 -20) . These cells also have a greater ability to form anchorage-independent floating spheres, proliferation, and tumor mass than the CD133Ϫve NSCLC cells. The CD133ϩve cells like CSC demonstrate significantly increased stemness, adhesion, motility, and expression of drug efflux gene (21) (22) (23) than CD133Ϫve tumor cells. Importantly, the presence of CD133ϩve tumor cells correlates well with poor prognosis, decreased survival, and increased lymph node metastasis in NSCLC patients (24 -26) .
Furthermore, in addition to CD133, aldehyde dehydrogenase 1 (ALDH1) is also used as a CSC marker in NSCLC (12, (27) (28) (29) (30) .
The ALDH1 activity is mainly due to its ALDH1A1 (aldehyde dehydrogenase 1 family, member A1) isoform, an intracellular cytosolic isoenzyme that oxidizes intracellular aldehyde and controls several functions including drug resistance (30) . Besides lung cancer, ALDH1A1 has also been used as a marker of CSC in breast and esophageal cancers (31, 32) . NSCLC cells expressing high ALDH1 activity show the characteristics of CSC such as increased proliferation, self-renewal, and resistance to chemotherapy in vitro, are highly tumorigenic in immunocompromised mice, and maintain heterogeneity like the parent tumors (27) . These ALDH1A1-expressing NSCLC cells are also known for their clone formation ability, proliferation, growth, and migration in vitro (28) .
On the contrary, silencing of ALDH1A1 in these cells results in considerable loss of their stem cell-like characteristics (28) . Importantly, reports from the clinics have indicated that ALDH1 expression is strongly associated with poor prognosis and lymph node metastasis in NSCLC (28, 29, 33) .
DA acts as a neurotransmitter regulating locomotor and behavioral functions (34) , and reports from our laboratory have indicated that in addition, DA can inhibit vascular endothelial growth factor-A (VEGF-A), mediating angiogenesis by suppressing VEGFR-2 phosphorylation (35) (36) (37) (38) . Studies from our laboratory have further reported that D 2 DA receptors can regulate different functions of normal progenitor and stem cells such as endothelial progenitor and mesenchymal stem cells (38, 39) . Therefore, it will be interesting to study the expression profile of D 2 DA receptors in the CD133ϩve tumor cell population in NSCLC and investigate the regulatory role of this neurotransmitter, if any, on the biology of this specific tumor cell population having CSC characteristics. Accordingly, we selected adenocarcinoma of the lung, the most common histological type of NSCLC observed in patients, for our present study.
Results

Association of CD133 and D 2 DA Receptors in Human
NSCLC-NSCLC is the most common type of lung cancer (2) . Among NSCLC patients, adenocarcinoma is predominant in both men and women (40) . Accordingly, we used human lung adenocarcinoma (NSCLC) patient tissue samples and cell lines A549 and NCI-H23 for our present study.
At first, we determined the expression of D 2 DA receptors in the CD133-expressing tumor cell population in NSCLC cell lines A549 and NCI-H23. After initial gating to exclude dead cells and debris (Fig. 1, A and B) , our FACS analysis demonstrated that in A549 and NCI-H23 cells, 22 and 20%, respectively, of the total tumor cells expressed D 2 DA receptors (Fig. 1,  C-F) , and 5 and 3.5%, respectively, of total A549 and NCI-H23 cells expressed CD133 (Fig. 1, G-J) . Furthermore, in both A549 and NCI-H23 cells, more than 95% of CD133ϩve cells expressed D 2 DA receptors (Fig. 1, K-N) . On the contrary, less than 16 and 15%, respectively, of CD133Ϫve cells in A549 and NCI-H23 expressed D 2 DA receptors (Fig. 1, K-N) .
We next validated this association in patient tissue samples. Our confocal data demonstrated significant co-localization of D 2 DA receptors with both stem cell markers, CD133 and aldehyde dehydrogenase (ALDH1A1), in human primary lung adenocarcinoma (NSCLC) tissue sections. More than 90% of the CD133 and ALDH1A1ϩve tumor cells in human NSCLC tissue sections co-expressed D 2 DA receptors in the CSC of human primary lung adenocarcinoma patients (Fig. 2) . Appropriate isotype-matched controls were used to determine the specificity of staining (data not shown).
After that, we isolated and enriched the CD133ϩve population from the human NSCLC cell line (A549) to study the significance, if any, of this high expression of D 2 DA receptors in these CD133ϩve CSC. Accordingly, experiments were undertaken with purified CD133ϩve NSCLC tumor cells (A549) to understand the biobehavior of this cell population following activation of D 2 DA receptors present in these cells. D 2 DA Receptor Stimulation Inhibits CD133ϩve NSCLC Tumor Cell Proliferation in Vitro-The 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay showed significant inhibition of proliferation in purified CD133ϩve NSCLC tumor cells when these cells were treated with 1 or 10 M quinpirole, a specific D 2 DA receptor agonist (Fig. 3A) . However, this action of quinpirole was abolished when these cells were pre-treated with a specific D 2 DA receptor antagonist, eticlopride (10 times more than the concentration of quinpirole), thereby further confirming the role of D 2 DA receptors (Fig. 3A) . On the contrary, 1 or 10 M quinpirole treatment had no significant effects on the proliferation of CD133Ϫve tumor cells (Fig. 3A) . Furthermore, FACS analysis did not demonstrate a significant number of annexin V-and propidium iodide (PI)-positive tumor cells following treatment with 1 or 10 M quinpirole treatment, thereby indicating that this low concentration of D 2 DA receptor agonist had no effects on the apoptosis of CD133ϩve NSCLC tumor cells (Fig. 3B) . (Fig. 4A) . Similarly, when these cells were treated with 10 M AKT inhibitor (LY294002) or 10 M ERK1/2 inhibitor (U0126), there was also significant inhibition of this characteristic of CD133ϩve NSCLC cells when compared with untreated controls. These results thus indicate that these signaling pathways play critical roles in inducing clone formation by CD133ϩve NSCLC tumor cells (Fig. 4A ). This observation was further validated from the sphere-forming ability of the tumor cells, a surrogate marker for stemness and the self-renewal ability of epithelial cancer cells (41) . In addition, CD133ϩve tumor cells, when treated with quinpirole (1 or 10 M) in serum-free medium, tumor cell sphere formation showed a significant decrease in number and size (Fig. 4 , B and C).
Inhibition of ERK1/2 and AKT in CD133ϩve NSCLC Tumor Cells following D 2 DA Receptor Activation-The CD133ϩve tumor cell population has been reported to overexpress activated ERK1/2 and AKT, and the inhibition of ERK1/2 and AKT significantly influences their clonogenic potential in colon cancer cells (42) . Our results also indicated the same in CD133ϩve NSCLC cells (Fig. 4A ). To explore D 2 DA receptor-mediated inhibition of the clonogenic ability of the CD133ϩve NSCLC tumor cells, we examined the effects of D 2 DA receptor activation on the status of ERK1/2 and AKT phosphorylation in this (Fig. 5A ). The concentrations of the scramble siRNA and D 2 DA receptor siRNA were optimized to ensure that they did not affect cell viability (data not shown), but significantly inhibited D 2 DA receptor expressions in the CD133ϩve NSCLC cells (Fig. 5B) . (43), we therefore determined the expression of Oct-4 in CD133ϩve NSCLC tumor cells. Untreated CD133ϩve NSCLC tumor cells expressed significant Oct-4 mRNA, as evident from real-time PCR (Fig. 6) . Interestingly, when this tumor cell population was treated with a specific D 2 DA receptor agonist, quinpirole, significant down-regulation of Oct-4 mRNA level was observed following treatment with 1 M (2.5-fold) or 10 M (10-fold) quinpirole. However, transfection of these tumor cells with D 2 DA receptor siRNA abrogated the inhibitory effect of quinpirole, thereby confirming the inhibitory role of D 2 DA receptor activation on OCT-4 expression in CD133ϩve NSCLC tumor cells (Fig. 6) .
Down-regulation of Oct-4 Expression in CD133ϩve NSCLC
Inhibition of CD133ϩve NSCLC Tumor Cells Invasion in Vitro following Activation of D 2 DA Receptors-As expression of CD133 in NSCLC tumor cells correlates with invasion and metastasis in lymph nodes (25) , we therefore investigated whether D 2 DA receptor activation in these CD133ϩve tumor cells in NSCLC has any effect on invasiveness of these cells. In our in vitro experiment, both the concentrations of quinpirole (1 M and 10 M) significantly inhibited the invasion of CD133ϩve NSCLC tumor cells through the Matrigel (Fig. 7, A and B) . D 2 DA Receptor Activation Inhibits MMP-9 Secretion by CD133ϩve NSCLC Tumor Cells-Matrix metalloproteinase-9 (MMP-9) plays a critical role in tumor cell invasion and metastasis (44). Our results indicated significant inhibition of MMP-9 concentration in the culture medium of D 2 DA receptor agonist quinpirole-treated cells after 24 h in comparison with untreated controls (Fig. 7C) .
D 2 DA Receptor Agonist, Quinpirole, Inhibited CD133ϩve A549 Non-small Cell Lung Cancer Tumor Cell Growth in Vivo-Similar to our in vitro experiments, on day 8, we also observed 47% inhibition of tumor growth in nude mice transplanted with CD133ϩve NSCLC tumor cells after treatment with 10 mg/kg i.p. of D 2 DA receptor agonist, quinpirole, for 7 days (Fig. 8) . We did not observe any significant side effects after treatment with this low dose of quinpirole, which corroborated with previous reports (45) .
Discussion
Taken together, our results for the first time indicate significant expression of D 2 DA receptors in CD133ϩve tumor cells in human adenocarcinoma of the lung (NSCLC) tumor tissues and cell lines. Importantly, cancer stem cell characteristics of this population of tumor cells are well established (18 -23) . Only a few other reports had indicated the presence of D 2 DA receptors in lung cancer cells (46) and inhibition of tumor growth following treatment with bromocriptine, a D 2 DA receptor agonist (47) . However, most of the other studies had been undertaken in large cell lung carcinoma and small cell lung carcinoma cells (48, 49) . The other study investigated the effects of D 2 DA receptor agonist on myeloid-derived suppressor cells and angiogenesis in lung cancer (50) . None of these reports mentioned the status of D 2 DA receptors and their effects on the treatment-refractory CD133ϩve CSC in adenocarcinoma of the lung, the most prevalent histological type of NSCLC (40) .
We demonstrate for the first time that stimulation of D 2 DA receptors present in the CD133ϩve CSC of NSCLC by a D 2 DA receptor agonist can inhibit their proliferation, clonogenic ability, and invasiveness in vitro (Figs. 3A, 4, A-C, and 7, A and B) , as well as suppressing tumor growth in vivo (Fig. 8) . The underlying mechanisms indicate that stimulation of D 2 DA receptors suppresses ERK1/2 and AKT phosphorylation (Fig. 5A) , resulting in inhibition of the clonogenic ability of these cells. Recent results indicate that this property of CSC is regulated through the ERK1/2 and AKT pathways (42) . Accordingly, it would be important to note that we and others had demonstrated D 2 DA receptor-mediated inhibition of ERK1/2 and AKT activation or Clonogenic ability is an important criterion of the stemness of CD133ϩve NSCLC tumor cells, and OCT-4 regulates this characteristic of these cells (43) . Our results indicate that activation of D 2 DA receptors significantly down-regulates OCT-4, and this correlates well with inhibition of tumor sphere formation, a surrogate marker of stemness (41) . Interestingly, recent evidence indicates that ERK2 also phosphorylates OCT4 and thus suggests that regulation of OCT4 is through activation of ERK (56) . AKT also phosphorylates OCT4 at threonine 235, and this action correlates with resistance to apoptosis and tumorigenesis (57) . Therefore, down-regulation of OCT4 in CD133ϩve NSCLC stem cells following stimulation of D 2 DA receptors in NSCLC cells may be due to inhibition of ERK1/2 and AKT phosphorylation following activation of D 2 DA receptors.
MMP-9 synthesis and release by tumor cells are associated with an invasive property of these cells leading to metastasis (44) . Reports further indicate an association of CD133ϩve NSCLC cells with lymph node metastasis, and high levels of MMP-9 correlate significantly with invasiveness of A549 NSCLC cells (58) . Therefore, our results demonstrating significant inhibition of MMP-9 synthesis by CD133ϩve tumor cells following treatment with quinpirole may be the cause of inhibition of Matrigel invasion by these cells.
Furthermore, in vivo xeno-transplanted human NSCLC cell line A549 also showed significant inhibition of tumor growth following treatment with D 2 DA receptor-specific agonist quinpirole, thereby supporting the in vitro results (Fig. 8) . These results, therefore, suggest the possibility of selectively targeting the CD133ϩve CSC population in NSCLC with a D 2 DA receptor agonist.
Finally, D 2 DA receptor agonists are already in use for the treatment of other disorders (59, 60) . Therefore, these agonists, together with the current conventional anticancer agents and/or radiotherapy, may be beneficial in the management of NSCLC patients as this combination of therapeutic approaches will not only eradicate the bulk of tumor cells, but may also eliminate the population of CSC that imparts resistance to therapy.
Experimental Procedures
Culture of NSCLC Cell Lines-Human NSCLC cell lines A459 and NCI-H23 procured from the National Center for Cell Sciences (Pune, India) were cultured in DMEM and RPMI 1640 (Life Technologies), respectively, with 10% FBS and penicillin/ streptomycin (50 units/ml). These cells were maintained at 37°C with a supply of 5% CO 2 . Cell lines were authenticated by short tandem repeat analysis (61) .
Patient Tissue Samples and Confocal Imaging-Human NSCLC tissue slides (adenocarcinoma of the lung) were obtained from thirty-five de-identified patients following the Institutional Review Board (IRB) rules of the Ohio State University and Chittaranjan National Cancer Institute. Characteristics of the patients are shown in Table 1 .
Slides were preblocked with 10% donkey serum at room temperature for 1 h. Thereafter, these slides were incubated with unconjugated primary antibodies for D 2 DA receptor (Santa Cruz Biotechnology), CD133 (Miltenyi Biotec), or ALDH1A1 (Santa Cruz Biotechnology) overnight at 4°C. On the next day, the slides were incubated with the respective secondary antibodies conjugated to fluorochrome for 1 h at room temperature, washed in PBS, and mounted with fluorescence mounting gel and DAPI (Electron Microscopy Sciences), and then confocal microscopy was performed (Olympus FBV 1000) (62) . All these antibodies have been previously validated by us and others (35, 38, (62) (63) (64) (65) (66) (67) (68) .
Flow Cytometry-Single cell suspension was stained with phycoerythrin-conjugated CD133/1 (Miltenyi Biotec, validated in several reports (69, 70) ) and fluorescein isothiocyanate-conjugated anti-DA D 2 antibodies (Santa Cruz Biotechnology, validated in our previous reports (38, 39)), either singly or in combination, for 30 min as per the recommendation of the manufacturer. Following labeling, the cells were washed in FACS buffer (PBS, pH 7.4, with 1% FBS) and fixed in 1% paraformaldehyde in PBS. Then flow cytometry was performed using CellQuest software (BD Biosciences). Appropriate negative isotype controls were used to rule out the background fluorescence. The percentage of each positive population and mean fluorescence intensities were determined using quadrant statistics (38) .
Isolation and Purification of CD133ϩve Cells by Magneticactivated Cell Sorting and Generation of Tumor
Sphere-The expression of CD133 was determined by flow cytometry (FACSCalibur, BD Biosciences) using CD133/1-phycoerythrin. 1 ϫ 10 7 cells were labeled with CD133/1 microbeads (Miltenyi Biotec), and the cell suspension was then loaded on a magneticactivated cell sorting column. The effluent containing the cell population enriched with the CD133ϩve cell fraction was collected. The purity of cells (Ͼ90%) was checked by flow cytometry after being labeled with CD133/1-phycoerythrin (Miltenyi Biotec). Mouse IgG1 phycoerythrin (Miltenyi Biotec) was used as isotype control. Thereafter, these purified CD133ϩve cells were suspended in stem cell medium containing serum-free DMEM/F12 supplemented with penicillin/streptomycin (50 units/ml), 20 ng/ml human recombinant epidermal growth factor (hrEGF), 10 ng/ml human recombinant basic fibroblast growth factor (hrbFGF), and 1% B27 supplement (Invitrogen), and then cultured in 6-well plates (Corning) at different densities as per the requirement varying from 1000 to 50,000 cells/ well. 1 or 10 M quinpirole (Sigma) was added to the medium. The sphere-forming efficiency was monitored following treatment by plating 1000 cells/well in 24-well cell culture plates and culturing them for 7 days with the appropriate controls. Sphere-forming efficiency was calculated by counting the number of tumor spheres formed in a given well and dividing this by the total number of living cells seeded in the well ϫ 100 (21) . This and other experiments were carried out in pooled CD133ϩve NSCLC cells.
Cell Proliferation by MTT Assay-Proliferation of CD133ϩve NSCLC cells in stem cell media was checked by the MTT assay as described previously (35) . In brief, 50,000 cells/well were seeded in 96-well round bottom cell plates (Corning) containing stem cell medium in the presence of 1 or 10 M quinpirole (Sigma) with or without eticlopride (10 times more than the concentration of quinpirole) and cultured for 72 h with the appropriate controls. The cells were pelleted, the medium was aspirated, and 20-l aliquots of MTT solution (5 mg/ml) (Sigma) were added and incubated for 4 h at 37°C. The medium was finally removed by aspiration, the purple-colored formazan precipitate was dissolved in DMSO (100 l), and then absorbance was measured at 550 nm using a microplate reader (BioTek).
In Vitro Tumor Apoptosis Assay-In vitro apoptosis of tumor cells was determined using the apoptosis detection kit (BD Pharmingen) as per the manufacturer's instructions. In brief, 1 ϫ 10 5 CD133ϩve tumor cells were incubated with or without quinpirole (in different doses for 72 h) at 37°C in a humidified atmosphere with 5% CO 2 . Cells were then washed with cold PBS, and then suspended in binding buffer and incubated with annexin V-FITC and propidium iodide for 15 min at room temperature in the dark. Apoptotic cells were monitored by flow cytometric analysis (38) .
siRNA Knockdown of D 2 DA Receptor-Cells were plated at 50% confluence on six-well plates. D 2 DA receptor siRNA (Santa Cruz Biotechnology) solution was diluted further with transfection medium (Santa Cruz Biotechnology), and then mixed with siRNA transfection reagent (Santa Cruz Biotechnology) and added to the culture medium to achieve a final siRNA concentration of 50 nmol/liter. Transfected cells were incubated at 37°C for 48 h. siRNA concentrations were optimized to ensure that they did not affect cell viability and scramble (51) . Scramble siRNA (Santa Cruz Biotechnology) was used as a control.
Matrigel Colony Formation Assay-The spheres collected by gentle centrifugation were dissociated by adding trypsin-EDTA followed by repeated pipetting. After determining cell viability by trypan blue staining, single cell suspension was seeded in DMEM with 10% FBS at a density of 4000 cells/well in 6-well plates that were precoated with Matrigel (BD Biosciences) and then treated with 1 or 10 M quinpirole. The colony formation ability was assessed after 7 days by counting the number of colonies (Ͼ70 cells) under a microscope following crystal violet staining (Sigma-Aldrich) (71) . To ascertain the effect of ERK and AKT inhibition on the colony-forming ability of CD133ϩve NSCLC cells in agarose, cells were treated with 10 M LY294002, AKT inhibitor (Cell Signaling Technology) or 10 M U0126, MEK1 inhibitor, and MEK2 inhibitor (42) was procured from Merck Millipore.
Preparation of Whole Cell Protein Lysates and Immunoblotting-To prepare whole cell lysates, CD133ϩve tumor cells were rinsed with PBS and disrupted with cell lysis buffer (20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 1% Triton X-100, 1 mM EDTA, 50 mM dithiothreitol, and 2 mM phenylmethylsulfonyl fluoride) and protease inhibitor cocktail (Sigma). The lysate was then spun down, cleared of debris by centrifugation, and assayed for total protein concentration using Bradford reagent (Bio-Rad). For immunoblotting analysis, protein samples were boiled in 1ϫ SDS buffer, separated by SDS-PAGE, and transferred to a PVDF membrane. The PVDF membrane was blocked with 0.2% I-BLOCK (Applied Biosystems) for 2 h at room temperature and incubated with the appropriate primary antibody overnight at 4°C. Finally, after washing with Trisbuffered saline (containing 0.1% Tween 20), each blot was incubated with the corresponding HRP-conjugated secondary antibody (Sigma), and the immunoblot signal was visualized by chemiluminescence reagents (Pierce) (72) . Primary antibodies used in this study were phospho-ERK1/2 from BD Transduction Laboratories (catalogue number 612358; lot number 99125) and phospho-AKT (1:500) from Santa Cruz Biotechnology (catalogue number SC7985-R; lot number AL909). The molecular weight markers were procured from Bio-Rad.
Quantitative Real-time PCR Analysis-Total RNA from treated and untreated CD133ϩve tumor cells was extracted using TRIzol reagent (Invitrogen). Total RNA (1 g) was reversely transcribed into cDNA using cDNA transcription kit (Applied Biosystems) and followed by quantitative real-time PCR analysis using the Universal SYBR Green Master Mix and
Step One Plus Real-Time PCR System (Applied Biosystems). ␤-actin was the endogenous control. The -fold expression of the target host gene was calculated by using the 2 Ϫ⌬⌬Ct formula (73) . The primers used were as follows: OCT4forward, 5Ј-TCGAGAACCGAGTGAGAGG-3Ј; OCT4 reverse, 5Ј-GAACCACACTCGGACCACA-3Ј; ␤-actin forward, 5Ј-CTG-GAGAAGAGCTACGAGC-3Ј; ␤-actin reverse, 5Ј-GGAT-GCCACAGGACTCCA-3Ј.
Matrigel Invasion Assay-Invasion assays were performed according to a previously published protocol (74) . Briefly, 1 ϫ 10 4 CD133ϩve NSCLC cells in 200 l of serum-free medium containing 1 or 10 M quinpirole were added to the upper chamber of a Matrigel insert (BD Biosciences), and 20% serum containing medium or medium without serum was placed in the lower chamber.
The plates were incubated for 24 h at 37°C in 5% CO 2 . The cells that did not migrate or invade through the pores were removed with a cotton swab, and cells on the lower surface of the membrane were examined, stained with crystal violet, and counted under a microscope. Supernatant from the upper chamber was collected, stored at Ϫ80°C, and used for the estimation of MMP-9. The invasion index was then calculated (74) .
ELISA of MMP-9 -To measure the extracellular secretion of MMP-9, cell-free supernatants were quantified by ELISA. In brief, 96-well microtiter plates were coated with cell-free supernatants and incubated overnight at 4°C. Plates were blocked with BSA (5%) for 2 h. After washing, 50 l of MMP-9 antibody (R&D Systems) diluted 1:1000 was added to each well and incubated for 45 min. Bound cytokine was detected with secondary IgG peroxidase (Sigma). The color was developed with 3,3Ј, 5,5Ј-tetramethylbenzidine (TMB) substrate solution (OptEIA TM , BD Pharmingen). The reaction was stopped with 2 N H 2 SO 4 solution, and absorbance was measured (450 nm) using a microplate reader (BioTek) (38) .
Xenotransplantation of Tumor in Nude Mice-Mice experiments were undertaken after approval by the Institutional Animal Care and Use Committee. Nude mice (National Institute of Nutrition, Hyderabad, India) 4 -6 weeks of age weighing 20 -25 g were used for the study. CD133ϩve tumor cells from A549 NSCLC tumor cell culture were purified by magnetic bead separation. Purified cells were further evaluated by flow cytometry to confirm Ն90% CD133ϩve tumor cells. Freshly isolated CD133ϩve tumor cells (10 4 ) were mixed with Matrigel (1:1) and inoculated subcutaneously in the right flank of each animal. When the tumor reached 100 mm 3 , animals were divided into two groups, each consisting of six animals. The control group received tumor cells ϩ Matrigel only, whereas the treated group received D 2 DA receptor agonist quinpirole (10 mg/kg) intraperitoneally for consecutive 7 days. Tumor volume was measured (TV (mm 3 ) ϭ d 2 ϫ d/2, where d and D are the shortest and longest diameter of the tumor) (62) .
Statistics-The results are expressed as mean Ϯ S.D. Statistical significance was determined using an unpaired Student's t test, and the results were considered significant when p Յ 0.05 (75) .
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